Business Context and Reporting Period
This Form 8-K was filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on January 15, 2021, reporting events occurring on January 14, 2021. The registrant is a Delaware corporation with principal executive offices in Berkeley Heights, NJ. Note: The request metadata references "Bio Green Med Solution, Inc.," but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive employment agreements and does not contain financial statements or performance metrics.
Material Changes
On January 14, 2021, the Company extended the employment agreements for two key executives, effective retroactively to January 1, 2021:
- Spiro Rombotis: President and Chief Executive Officer.
- Paul McBarron: Executive Vice President-Finance, Chief Financial Officer, and Chief Operating Officer.
The term of these agreements was extended for an additional six months, through June 30, 2021. All other terms remain unchanged from the agreements previously disclosed in a Form 8-K filed on January 7, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document serves solely to disclose the extension of executive employment contracts.
Investor Verification Checklist
- Verify the correct registrant name is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Confirm the new expiration date of the CEO and CFO employment agreements is June 30, 2021.
- Review the original employment agreements filed on January 7, 2019, to understand the unchanged compensation terms.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.